Eli Lilly's Shares Rise 0.66% Amid Texas Lawsuit Claims as $4.42 Billion Volume Secures 13th Market Rank

Eli Lilly's shares rose 0.66% on August 12, 2025, with a trading volume of $4.42 billion, marking a 38.98% decline from the previous day's activity and securing the 13th position in market volume rankings. This performance coincided with a significant legal development as Texas Attorney General Ken Paxton filed a lawsuit against the pharmaceutical giant, alleging illegal kickbacks to medical providers to promote its blockbuster GLP-1 drugs Mounjaro and Zepbound. The lawsuit claims the company engaged in an "illegal kickback scheme" to influence prescribing decisions for its most profitable weight-loss and diabetes treatments.

The legal action expands Paxton's ongoing efforts to hold Big Pharma accountable, following prior suits against insulin manufacturers and pharmacy benefit managers. Eli Lilly has dismissed the allegations as stemming from a "corporate relator" whose claims were previously dismissed by courts and federal authorities. The company reiterated its commitment to challenging the accusations, citing prior rulings that deemed the claims lacking in factual and legal merit. The lawsuit could heighten regulatory scrutiny for the firm, particularly as its GLP-1 portfolio remains central to its recent growth strategy.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day resulted in a moderate return of $2,340 between 2022 and the present. However, the approach faced a maximum drawdown of -15.3% on October 27, 2022, underscoring the inherent risks of short-term trading strategies in volatile markets.